TESARO, Inc. Appoints Robert E. Martell, M.D., Ph.D. as Chief Medical Officer
WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the appointment of Dr. Robert Martell as Chief Medical Officer. Dr. Martell is a practicing medical oncologist at Tufts Medical Center who brings extensive drug development experience to TESARO from both industry and academia. He most recently served as Associate Professor of Medicine and Molecular Physiology and Pharmacology, Tufts University School of Medicine; Director, Neely Center for Clinical Cancer Research; and Leader of the Experimental Therapeutics Program at Tufts Medical Center Cancer Center.
Dr. Martell previously held positions of increasing responsibility within oncology drug development at Bristol-Myers Squibb, Bayer, and MethylGene, where he served as Chief Medical Officer. He has led the clinical development of, and been associated with regulatory submissions for several anti-cancer agents, and has authored numerous scientific publications.
"Bob brings to TESARO considerable oncology experience and a proven track record in advancing the clinical development of innovative therapies for cancer patients," said Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer. "His appointment is an important step in building our senior team as we advance the development of rolapitant, niraparib and TSR-011 and work toward achieving our mission to make a difference in the lives of cancer patients."
Dr. Martell received a doctorate in Pharmacology from the University of Michigan and his medical degree from Wayne State University School of Medicine. He completed his internship and residency training in Internal Medicine and Fellowship training in Oncology at Duke University Medical Center and had subsequent clinical appointments at Duke University Medical Center, Durham VA Medical Center, Yale University School of Medicine and Tufts Medical Center.
About TESARO
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
Statements contained in this press release that are not descriptions of historical facts regarding TESARO, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include our expectations regarding the continued development of our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Prospectus filed with the Securities and Exchange Commission (SEC) on June 29, 2012 and TESARO's Form 10-Q for the quarter ended June 30, 2012, filed with the SEC on July 27, 2012.
CONTACT: Richard Rodgers
Executive Vice President & CFO
+1.339.970.0903
[email protected]